Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women's cancers. The Company's lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 07/24/20 | $54,000,000 | Series B |
BVF Partners Cormorant Asset Management Foresite Capital Janus Henderson Investors Logos Capital RA Capital Management Surveyor Capital Venrock Healthcare Partners Wellington Management Company | undisclosed |
